share_log

Avalo Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Point72 Asset Management, L.P.(0.3%),Point72 Capital Advisors, Inc.(0.3%), etc.

SEC announcement ·  Feb 14 10:08
Summary by Moomoo AI
Avalo Therapeutics, Inc., a biotechnology company, has been the subject of a recent Schedule 13G/A filing with the Securities and Exchange Commission (SEC) as of December 31, 2023. The filing was made by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen, indicating a shared voting and dispositive power over 2,500 shares of Avalo Therapeutics' common stock, issuable upon exercise of warrants. These shares represent a 0.3% ownership of the class. The filing entities have entered into a Joint Filing Agreement, suggesting a coordinated approach to the filing. The address for Point72 Asset Management and Point72 Capital Advisors is in Stamford, CT, and both entities are organized under the laws of Delaware. Steven A. Cohen is identified as a United States citizen. The filing...Show More
Avalo Therapeutics, Inc., a biotechnology company, has been the subject of a recent Schedule 13G/A filing with the Securities and Exchange Commission (SEC) as of December 31, 2023. The filing was made by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen, indicating a shared voting and dispositive power over 2,500 shares of Avalo Therapeutics' common stock, issuable upon exercise of warrants. These shares represent a 0.3% ownership of the class. The filing entities have entered into a Joint Filing Agreement, suggesting a coordinated approach to the filing. The address for Point72 Asset Management and Point72 Capital Advisors is in Stamford, CT, and both entities are organized under the laws of Delaware. Steven A. Cohen is identified as a United States citizen. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics and were not acquired in connection with any transaction having such purpose or effect. The filing includes a certification of accuracy and completeness signed by Jason M. Colombo, an authorized person for all three reporting entities.

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more